Orion (ORNBV.HE) Stock Analysis & AI Equity Report
Orion (ORNBV.HE) overview
Orion (ORNBV.HE) stock analysis and AI equity research. For the latest completed financial year, 2024, Orion reported revenue of EUR 1,542m and operating profit of EUR 417m; the year-end share price was 42.78 EUR and market capitalisation was EUR 6,010m. Orion is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Orion's valuation, value-pool analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Orion
Orion is a Finnish pharmaceutical company that develops, manufactures and markets medicines and related healthcare products. Its portfolio includes proprietary and generic drugs, self-care products such as non-prescription medicines, vitamins and skincare products, veterinary medicines and animal well-being products, and active pharmaceutical ingredients. Its products are sold in more than 100 countries.
Generate the Orion report
Orion is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Orion and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.